

Esophageal Oncology group : Treatment map Jan.2025.

UICC 8th	Standard treatment in Japan		Trials ongoing or follow up		
Stage I (N0)	Endoscopic resection (ESD/EMR) + CRT		JCOG2013 (±NeoCF ² /DCF ³) Esophagectomy: Upper and Middle thoracic Esophageal Squamous Cell Cancer SCLN ⁸ Dissection vs Preservation 2022/8~ Ongoing	JCOG1904 CRT: IFI ⁵ vs. ENI ⁶ 2020/03~ Ongoing	
	Esophagectomy (Thoracoscopic or open esophagectomy) ¹	Concurrent CRT (CF-RT ⁴)			
Stage I (N1)			JCOG2206 NeoCF ² /DCF ³ +Esophagectomy: Surgery alone vs Nivolumab vs S-1 2023/7~ Ongoing	JCOG2203 Adenocarcinoma of EGJ ⁹ Esophagectomy: Upfront surgery vs Neo DOS ¹⁰ /FLOT ⁷ 2023/7~ Ongoing	
Stage II	Neoadjuvant chemotherapy (Neo DCF ³) + Esophagectomy (Thoracoscopic or open esophagectomy) ¹	Adjuvant Nivolumab (Neo CRT + Esophagectomy)			
Stage III		Concurrent CRT (CF-RT ⁴) (+Salvage esophagectomy or endoscopic resection)			
T4a/M1LYM Resectable	Neoadjuvant chemotherapy + Esophagectomy ¹	Concurrent CRT	JCOG1510 Concurrent CRT vs. Induction DCF ³ + Concurrent CRT or Esophagectomy 2018/2~ Follow up period		
T4b/M1LYM Unresectable	Concurrent CRT				
Stage IVB	1 st line chemotherapy: CF ² + Pembrolizumab CF ² + Nivolumab Nivolumab + Ipilimumab	2 nd line chemotherapy: Paclitaxel Docetaxel If no previous ICIs ¹¹ : Nivolumab Pembrolizumab (CPS ≥10)	JCOG2311 Radiation therapy + Nivolumab + Ipilimumab vs. Nivolumab + Ipilimumab 2014/11~ Ongoing		
Recurrent					

1) 2-3 field lymph node dissection 2) CF, CDDP + 5-FU 3) DCF, DOC + CDDP + 5-FU 4) CF-RT, CDDP + 5-FU + radiation therapy
5) IFI, Involved field irradiation 6) ENI, Elective lymph node irradiation 7) FLOT, 5-FU + LV + L-OHP + DOC 8) SCLN, Supraclavicular lymph node
9) EGJ, Esophagogastric junction 10) DOS, DOC + L-OHP + S-1 11) ICI, Immune checkpoint inhibitor